UNSPSC 51322403: Dirlotapide

This classification denotes an anorexiant with the molecular formula C40H33F3N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 578H0RMP25, chemically known as 1h-indole-2-carboxamide, 1-methyl-n-((1s)-2-(methyl(phenylmethyl)amino)-2-oxo-1-phenylethyl)-5-(((4-(trifluoromethyl)(1,1-biphenyl)-2-yl)carbonyl)amino)- but generally known as dirlotapide, which bears US NIH Compound Identifier 6433125. The term DIRLOTAPIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53).

UNSPSC 51322403 Dirlotapide, a Commodity code, encompasses pharmaceutical products supplied to state and local emergency medical services, health agencies, and cooperative purchasing alliances. State and local governments buy dirlotapide and related advanced life support medications through competitive sealed-bid procurements and multistate cooperative purchasing vehicles, with suppliers required to meet strict expiration-date minimums, OSHA hazard communication compliance, and FDA manufacturing standards. The issuing bodies include city fire rescue departments, state health and human services commissions, and cooperative purchasing organizations representing multiple jurisdictions. Work under this code spans routine medication replenishment for emergency medical response, participation in direct-to-manufacturer pharmacy initiatives, and enrollment in established multistate generic pharmaceutical frameworks that aggregate demand across state agencies and local facilities.

The code shows recent activity across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications to Tampa Fire Rescue (due April 8, 2026), soliciting 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem for a $40,000 estimated contract value with a one-year term and renewal options, using a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs supporting pharmacy benefit operations across state agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and a two-year contract term. Suppliers must maintain authorization with at least two of three designated wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, and carry $5 million in commercial general liability insurance.